The Alzheimer’s field is entering a new era. New, blood biomarker tests represent a major advancement as a diagnostic tool and could soon be used as a more readily accessible screening tool to identify key indicators of early Alzheimer’s. The science is ready. The bipartisan Alzheimer’s Screening & Prevention (ASAP) Act would ensure Medicare coverage keeps pace and momentum is building in Congress to pass this legislation. The following is a compilation of what policymakers,
